A Phase 1, Randomized, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of SBS-101 After Intraoral Application in Patients With Oral Premalignant Lesions (OPL)
Latest Information Update: 21 Oct 2021
At a glance
- Drugs Isotretinoin (Primary)
- Indications Leucoplakia; Mouth disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Skyline Biosciences
Most Recent Events
- 11 Oct 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Oct 2020 Planned End Date changed from 1 Apr 2021 to 1 May 2023.
- 23 Oct 2020 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2023.